Body-surface area-based chemotherapy dosing: Appropriate in the 21st century?

Journal of Clinical Oncology

Volumn 30, Issue 31, 2012, Pages 3896-3897

  Beumer, Jan H ^a   Chu, Edward ^a   Salamone, Salvatore J ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b SALADAX BIOMEDICAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; FLUOROURACIL; PACLITAXEL;

BODY SURFACE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG EXPOSURE; DRUG MONITORING; HUMAN; LETTER; MAXIMUM TOLERATED DOSE; OBESITY; OVERALL SURVIVAL; PATIENT CARE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; DRUG DOSAGE CALCULATIONS; HUMANS; NEOPLASMS; OBESITY;

EID: 84869123512     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.2863     Document Type: Letter

References (17)

1. Griggs JJ, Mangu PB, Anderson H, et al: Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 30:1553-1561, 2012
2. Du Bois D, Du Bois EF: A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 5:303-311; discussion 312-313, 1989
3. Pinkel D: The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 18:853-856, 1958
4. Baker SD, Verweij J, Rowinsky EK, et al: Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 94:1883-1888, 2002 (Pubitemid 36104633)
5. Felici A, Verweij J, Sparreboom A: Dosing strategies for anticancer drugs: The good, the bad and body-surface area. Eur J Cancer 38:1677-1684, 2002
6. de Jonge ME, Huitema AD, Schellens JH, et al: Individualised cancer chemotherapy: Strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation - A review. Clin Pharmacokinet 44:147-173, 2005 (Pubitemid 40188938)
7. Hon YY, Evans WE: Making TDM work to optimize cancer chemotherapy: A multidisciplinary team approach. Clin Chem 44:388-400, 1998 (Pubitemid 28087746)
8. Rudek MA, Sparreboom A, Garrett-Mayer ES, et al: Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer 40:1170-1178, 2004 (Pubitemid 38526335)
9. Saif MW, Choma A, Salamone SJ, et al: Pharmacokinetically guided dose adjustment of 5-fluorouracil: A rational approach to improving therapeutic outcomes. J Natl Cancer Inst 101:1543-1552, 2009
10. Takimoto CH: Maximum tolerated dose: Clinical endpoint for a bygone era? Target Oncol 4:143-147, 2009
11. Bruno R, Hille D, Riva A, et al: Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187-196, 1998 (Pubitemid 28041598)
12. Gamelin E, Delva R, Jacob J, et al: Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26:2099-2105, 2008
13. Gianni L, Kearns CM, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995
14. Joerger M, Huitema AD, Richel DJ, et al: Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: A study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group. Clin Cancer Res 13:6410-6418, 2007 (Pubitemid 350075031)
15. Jodrell DI, Egorin MJ, Canetta RM, et al: Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520-528, 1992
16. Miller AA, Rosner GL, Egorin MJ, et al: Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res 10:8325-8331, 2004 (Pubitemid 40053393)
17. Capitain O, Asevoaia A, Boisdron-Celle M, et al: Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: A phase II, proof-of-concept study. Clin Colorectal Cancer [epub ahead of print on June 8, 2012]